Bionomics expands vascular disrupter programme to mesothelioma
This article was originally published in Scrip
Executive Summary
The Australian venture Bionomics is to begin a Phase II trial investigating its vascular disrupting anticancer agent BNC105 as a second-line treatment for mesothelioma.